Literature DB >> 12067978

Ecteinascidin-743 inhibits activated but not constitutive transcription.

Debbie Friedman1, Zhen Hu, E Anders Kolb, Barbara Gorfajn, Kathleen W Scotto.   

Abstract

Ecteinascidin-743 (ET-743) is a promising chemotherapeutic agent currently in Phase III clinical trials. Previous studies indicated a novel spectrum of activity for this agent, including transcriptional inhibition. Initially hypothesized to target a single transcription factor (NF-Y), we now show that ET-743 is a more general inhibitor of activated transcription. Induction of the Sp1-regulated p21 gene by Trichostatin A (TSA) was blocked by ET-743 at concentrations that had minimal effect on uninduced (constitutive) expression. Moreover, ET-743 blocked induction of Gal4 fusion proteins by TSA without affecting activation mediated by the fusion proteins in the absence of the inducer. Finally, microarray analysis of SW620 cells treated with TSA and/or ET-743 indicated that activation of TSA-responsive promoters was blocked by ET-743 with little affect on nonresponsive promoters. These results, taken together with previous reports, leads us to suggest a mechanism whereby ET-743 is a novel, potent, and general inhibitor of activated but not uninduced transcription.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067978

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

2.  A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.

Authors:  Axel Le Cesne; Alejandro Yovine; Jean-Yves Blay; Suzette Delaloge; Robert G Maki; Jean-Louis Misset; Pilar Frontelo; Antonio Nieto; Juhui James Jiao; George D Demetri
Journal:  Invest New Drugs       Date:  2011-04-12       Impact factor: 3.850

3.  Cockayne syndrome group B protein (CSB) plays a general role in chromatin maintenance and remodeling.

Authors:  John C Newman; Arnold D Bailey; Alan M Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-13       Impact factor: 11.205

4.  Myriaporone 3/4 structure--activity relationship studies define a pharmacophore targeting eukaryotic protein synthesis.

Authors:  John Hines; Myriam Roy; Hua Cheng; Christina M Agapakis; Richard Taylor; Craig M Crews
Journal:  Mol Biosyst       Date:  2006-05-26

5.  A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.

Authors:  Meredith K Chuk; Alberta Aikin; Trish Whitcomb; Brigitte C Widemann; Peter Zannikos; Eliel Bayever; Frank M Balis; Elizabeth Fox
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

6.  Role of trabectedin in the treatment of soft tissue sarcoma.

Authors:  Alexandre Christinat; Serge Leyvraz
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

7.  New developments in treatment of ovarian carcinoma: focus on trabectedin.

Authors:  Philippe A Cassier; Aude Duret; Olivier Trédan; Nicolas Carrabin; Pierre Méeus; Isabelle Treilleux; Jean-Paul Guastalla; Isabelle Ray-Coquard
Journal:  Cancer Manag Res       Date:  2010-10-01       Impact factor: 3.989

Review 8.  Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

Authors:  Natalie J Carter; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

Authors:  Gregory J Aune; Kazutaka Takagi; Olivier Sordet; Josée Guirouilh-Barbat; Smitha Antony; Vilhelm A Bohr; Yves Pommier
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

10.  Microarray-based transcriptional profiling of renieramycin M and jorunnamycin C, isolated from Thai marine organisms.

Authors:  Kornvika Charupant; Khanit Suwanborirux; Naomi Daikuhara; Masashi Yokoya; Rie Ushijima-Sugano; Takatoshi Kawai; Takashi Owa; Naoki Saito
Journal:  Mar Drugs       Date:  2009-10-19       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.